November 3, 2025

NRG Oncology Broadcast archives are accessible from our website at any time. Please bookmark this link for your convenience.

NRG Oncology Adds New Leadership Members to Ancillary Projects, Brain Tumor, Breast Cancer, and Patient Advocate Committees

Read the Press Release



Reminder, the following clinical trials are open to enrollment. Please continue to review your patient population and discuss enrollment opportunities with your clinical teams. All protocol related documents are posted on CTSU.

NRG-CC015/HEAL-ABC is a study examining mindfulness training to improve mental health and well-being in younger breast cancer survivors (between ages 18 and 51 at time of diagnosis) with symptoms associated with depression.

NRG-GU008 is recruiting patients who have node-positive prostate cancer and need more treatment after prostatectomy.

NRG-GU011 is open to enrollment for patients with oligometastatic prostate cancer – only 34 patients to go! Please help us complete this trial.

NRG-GU012: Reminder, the maximum number of accrual of non-clear cell patients is 48. Currently, there are 13 patients registered who have this type of histology. Please continue to screen patients with this histology.

TERMINATIONS

GYNECOLOGIC

GOG-0263: Terminated October 27, 2025; version date: March 14, 2022 (posted on CTSU)

GOG-0281: Terminated October 27, 2025; version date: November 29, 2022 (posted on CTSU)

AMENDMENT

GYNECOLOGIC

NRG-GY026: Amendment 9; version date: October 16, 2025 (posted on CTSU) 

FORM UPDATE

BRAIN

NRG BN011: The Patient History form has been updated. The updated form is posted on CTSU. Please begin using the new form immediately. 



OTHER PROTOCOL NOTICES

1. ALL DISEASE SITES

NRG-GY022: Reminder: Actively Recruiting MALE Patients only. Read More

2. BIOSPECIMEN BANK

Printing Biospecimen Transmittal PDFs from Rave

Please note an effort is underway to clarify how to obtain a Biospecimen Transmittal PDF for submission to the NRG Oncology Biospecimen Bank. Read More

Kit Shipments to Sites in Canada

Important information re: shipments of kits from BB Columbus to Sites in Canada. Please see the memorandum, dated August 18, 2025, posted on CTSU.

3. CANCER PREVENTION & CONTROL

NRG-CC005/FORTE: Clinical research professionals can sign up for NRG Oncology Weekly Broadcasts to receive monthly FORTE Fridays updates directly to your inbox (click here).

4. GASTROINTESTINAL

NRG-GI012: Updated Biospecimen Manual, dated October 24, 2025, posted on CTSU.

5. GYNECOLOGIC

NRG-GY020: Approaching its final analysis. To provide the investigators with the most accurate information, please submit all overdue data and update any outstanding patient data queries by December 1, 2025.

NRG-GY026: Accruing patients of all stages and all histologic subtypes of endometrial cancer.

NRG-GY031: Please note there is an error in the section 4.2 table and the Biospecimen Collection and Submission Manual. The Part I PK collection is to be done on Cycle 1, Day 1, and Cycle 1, Day 8. This will be updated with the next amendment.

NRG-GY037 requires blocks to be submitted, but the study team recognizes variations in site operating procedures to release blocks. Please refer to the Letter to Pathologists in the Biospecimen Collection and Submission Manual. If your site is experiencing any issues with this requirement, please contact the study team as we can work with sites on a case-by-case basis to ensure patients have an opportunity to participate in this trial.

6. HEAD & NECK

NRG-HN008: Reminder: Please update treatment and AE data weekly. This is a Phase I trial and timely data submission is very important.

7. LUNG

NRG-LU008: Attn sites in Canada – Amendment 3 was approved by Health Canada. The NOL and forms are posted on CTSU. Please submit the completed CTSI and protocol signature page via the CTSU regulatory portal.

8. VTOC TRAINING

For all NRG studies that use VTOC (Vision Tree Optimal Care): It has come to our attention that although Vision Tree has whitelisted their domain, Yahoo and AT&T have strong filters for spam that have been prohibiting participants from getting their emails. Please ask participants to 1) save the email address (fasttrack@optimalcare.com) as a contact or 2) suggest an alternative email (i.e. gmail is a successful alternative) when setting up their accounts.



The VTOC Webinar Training Series schedule and registration is available for NRG Oncology Research Associates working on NRG-BN014, NRG-BR009, NRG-CC005, NRG-CC011, NRG-CC013, NRG-CC014, NRG-CC015, NRG-GI011, NRG-GI012, NRG-GU015, and NRG-HN014. Space is limited so register now and reserve your seat. The next webinar training is scheduled for November 12, 2025.

1. NRG Oncology System Updates – Upcoming Participant Entry Downtime

NRG Oncology will be implementing system updates on Sunday, November 9, 2025. Participant randomization to NRG Oncology studies will not be available from Sunday, November 9 beginning at 7 am ET through Monday, November 10 7am ET. This is the first of two NRG Oncology system updates that will be conducted before the end of the year 2025. The second update is currently planned to occur from Friday, November 21, 2025, at 5pm ET through Sunday, November 23, 2025.

Confirmation of the November 21-23 dates will be provided in a future broadcast once known and as soon as possible. Please plan accordingly. Questions should be directed to support@nrgoncology.org. 

2. Publication Policy and Guidelines

The NRG Oncology Publication Policy and Guidelines have been revised and a new version is posted here on our website. Major updates include:

• Alignment with the NIH Public Access Requirements that became effective July 1, 2025
• Implementation of a mandatory manuscript planning process for primary endpoint result reporting.
• Requirements for NRG Oncology endorsement for treatment atlases, white papers and review papers.
• Authorship agreements encouraged pre-activation for studies with complex development processes (i.e., collaborations between multiple committees or organizations)
• Approval process for co-first/last authorships clarified.
• Reassignment of authorship if timelines are not met is emphasized.
• A collaborating author group may be added to primary endpoint manuscript author lines to recognize contributors from high-accruing institutions, per journal guidelines.
• Preprinting of non-final manuscripts in non-peer-reviewed repositories is prohibited without committee approval.
• Biobank personnel with significant contributions should be considered for authorship.
• Publications with Ancillary, Translational Science, and Physics Analyses may provide authorship for current applicable committee chairs managing major accrual or research work.

7. NRG Oncology Current Committee Leadership Openings

• Vice Chair, Publications Committee
  Deadline extension: Applications DUE November 18, 2025 - Read more & How to Apply

8. NRG Mentorship Subcommittee Update

Are you a new CRA or CTN within NRG Oncology? Would you like a mentor to help guide you through your new role as a CRA or CTN? Are you an institution in need of more guidance after an audit? The Mentorship Subcommittee can provide you with a mentor! You can apply for a mentor by going to the Introductory Materials page on the NRG website. You will find the Mentor Form to complete. The instructions on how to submit are located on the form. Hope to hear from you soon!

9. Veterans Day Closure Information

Please note the following NRG Oncology locations will be closed on Tuesday, November 11, 2025, in observance of Veterans Day: Philadelphia East Operations Center, Buffalo SDMC, and the Biospecimen Bank in San Francisco. All other locations will be open during regular business hours.

10. NRG Member Information Form

We are excited to introduce the NRG Member Information Data Collection Initiative that will allow us to create a comprehensive member database, enabling us to better understand and serve our members. Your information will be kept secure and confidential, ensuring that your privacy is always protected. All members are encouraged to complete the form or indicate that they wish to opt out of this data collection initiative. 

Scan the QR code below or click this link to access the form. 

Questions? Read more here

NRG Oncology is pleased to report the abstracts accepted for presentation at the 2026 ASCO Gastrointestinal Cancers symposium.

This publications report includes links, when available, to the article, PubMed abstract, or association abstract

ACCEPTED ABSTRACTS

Lieu CH, Yu G, Kopetz S, Jacobs SA, Lucas PC, Sahin IH, Deming DA, Philip PA, Hong TS, Rojas-Khalil Y, Loree J, Wolmark N, Yothers G, George TJ, Dasari A. NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA). ASCO GI; January 8-10, 2026. Poster Session, 1/10/2026; Abstract # TPS256.

Rocha Lima C, Yothers G, Jacobs SA, Sanoff HK, Cohen DJ, Guthrie KA, Henry NL, Ganz PA, Kopetz S, Lucas PC, Blanke CD, Hong TS, Wolmark N, Hochster HS, George TJ, Overman MJ. Colorectal cancer metastatic dMMR Immuno-Therapy (COMMIT) study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC): NRG-GI004/SWOG-S1610. ASCO GI; January 8-10, 2026. Oral Abstract Session C, 1/10/2026; Abstract # 14.

Please note the following upcoming meetings and abstract submission deadlines

UPCOMING MEETINGS

American Radium Society (ARS) Annual Meeting; Apr 30-May 3, 2026; Newport Beach, CA

American Society of Clinical Oncology (ASCO) GI; Jan 8-10, 2026; San Francisco, CA

International Gynecologic Cancer Society (IGCS); Nov 5-7, 2025; Cape Town, South Africa

Radiological Society of North America (RSNA); Nov 30-Dec 4, 2025; Chicago, IL

San Antonio Breast Cancer Symposium (SABCS); Dec 9-12, 2025; San Antonio, TX

Society for Neuro-Oncology (SNO); Nov 19-23, 2025; Honolulu, HI

Society for Immunotherapy of Cancer (SITC); Nov 5-9, 2025; National Harbor, MD

Society of Surgical Oncology (SSO) – Advanced Cancer Therapies; Feb 14-16, 2026; Fort Lauderdale, FL

Society of Urologic Oncology (SUO); Dec 2-5, 2025; Dallas, TX

UPCOMING ABSTRACT SUBMISSION DEADLINES

American Association for Cancer Research (AACR); Apr 17-22, 2026; San Diego, CA; Due to publications committee Nov 4, 2025; Submission deadline Nov 18, 2025, 11:59 pm ET; LBA and Clinical Trials Jan 6, 2026, 11:59 pm ET

American Head & Neck Society (AHNS) Annual Meeting; Jul 18-22, 2026; Boston, MA; Due to publications committee Nov 21, 2025; Submission deadline Dec 5, 2025, 5:00 pm ET

American Society of Breast Surgeons (ASBrS); Apr 29-May 3, 2026; Seattle, WA; Submission deadline Nov 6, 2025, 12:00 am PT; LBA Jan 9, 2026, 12:00 am PT

American Society of Clinical Oncology (ASCO); May 29-Jun 2, 2026; Chicago, IL; Due to publications committee Jan 13, 2026; Submission deadline Jan 27, 2026, 11:59 pm ET; LBA Mar 9, 2026, 12:00 pm ET (placeholder required)

American Society of Clinical Oncology (ASCO) GU; Feb 26-28, 2026; San Francisco, CA; LBA Nov 20, 2025, 12:00 pm ET (placeholder required)

American Society of Colon and Rectal Surgeons (ASCRS); May 9-12, 2026; Tampa, FL; LBA and Clinical Trials Jan 28, 2026

European Society of Gynaecological Oncology (ESGO); Feb 26-Mar 1, 2026; Copenhagen, Denmark; LBA Jan 15, 2026

American Society for Radiation Oncology (ASTRO); Boston, MA; Sep 27-30, 2026; Due to publications committee Feb 10, 2026; Submission deadline Feb 24, 2026; LBA Apr 20, 2026 (placeholder required)

ESMO (European Society for Medical Oncology) Breast; May 6-8, 2026; Berlin, Germany; Due to publications committee Jan 13, 2026; Submission deadline Jan 27, 2026, 21:00 CST; LBA Mar 31, 2026, 21:00 CST (placeholder required)

European Society for Radiotherapy and Oncology (ESTRO); May 15-19, 2026; Stockholm, Sweden; Submission deadline Nov 12, 2025; LBA Apr 8, 2026

Miami Breast Cancer Conference; Mar 5-8, 2026; Miami, FL; Due to publications committee Dec 22, 2025; Submission deadline Jan 5, 2026, 5:00 pm ET



Society of Surgical Oncology (SSO) – Annual Meeting; Mar 5-7; Phoenix, AZ; LBA Dec 1, 2025, 11:59 pm CT